INmune Bio Inc. Overview
Pro stress-test →INmune Bio is a clinical-stage immunology company focused on developing drugs to reprogram the patient's innate immune system to treat hematologic malignancies, solid tumors, and chronic inflammation. The company operates three distinct product platforms targeting unmet needs in oncology, neurodegenerative diseases, and inflammatory conditions.
Strategic Profile
Pro stress-test →The Dominant-Negative TNF (DN-TNF) Platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. Key development programs include INKmune (Phase 1 for high-risk myelodysplastic syndrome), INB03 (Phase II for breast cancer), and XPro1595 (for Alzheimer's disease and treatment resistant depression).
Competitive Landscape
Pro stress-test →INmune Bio is a publicly traded clinical-stage biotechnology company competing in the immunotherapy space against larger established players and other clinical-stage biotech firms. The company's precision medicine approach targeting innate immune dysfunction differentiates it from broader immunotherapy platforms, though it faces intense competition from well-capitalized CAR-T and checkpoint inhibitor developers.
Industry Context
INmune Bio Inc. operates in Clinical-Stage Biotechnology / Immunotherapy.
Key facts
Founded: 2015 · Headquarters: Boca Raton, Florida · Revenue: $14,000 (2024)